Reimagining Medicine
Company overview
Financial review
Conclusions
Appendix
References
Sandoz delivered several consecutive quarters of growth, with a
strong Q2 performance and ambitious mid-term outlook
STRATEGY
Q2 performance¹
Mid-term guidance for
standalone Sandoz
Sales growth rates¹ in cc
+4%
+8%
+8%
FY 2022 Q1 2023
Q2 2023
Sales USD 2.4bn, +8%
Biosimilars +13%; Generics +6%
Strong ex-US sales growth driven by EU
(USD 1.3bn, +13%)
Core Oplnc +6%
FY 2023 guidance: Sales expected to
grow mid single digit; Core Oplnc to
decline low double digit
Sales1
Mid-single digit CAGR
Core EBITDA margin
Approximately 24-26%
Dividend Policy
30-40% of core net income
1st payment in 2024
for 2023 performance
(20-30% of FY core net income)
1. All growth rates in constant currencies (cc).
25 Investor Relations | Q2 2023 Results
Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report.
✓ NOVARTIS | Reimagining MedicineView entire presentation